FDA warns of risks with unapproved, compounded weight loss drugs

What’s in this report:Weight loss drugs: What’s behind the FDA’s warning?Cheap GLP-1s online? Know the red flags.Fake labels, warm shipments and dosing mistakes: What to watch for.ATLANTA, Ga. (Atlanta News First) - The Food Drug Administration (FDA) is warning patients and doctors about the risks of unapproved, compounded versions of popular GLP-1 weight loss drugs, the compounded copies of semaglutide and tirzepatide, not the FDA-approved brand-name drugs themselves. Compounded versions are not reviewed by the FDA for safety, effectiveness or quality before they’re sold. The FDA says to be wary of telehealth companies that: Claim their drug is “the same as” an FDA-approved version.Offer prices that seem too good to be true. Ship medicine that looks different than before, or arrives damaged. Skip a doctor screening before sending medication. Have no doctor available to answer questions afterward. Have label typos or list a wrong pharmacy address.Some compounded products carry labels